Following the approval of CLINUVEL’s lead product SCENESSE® (afamelanotide 16mg), the Company is actively pursuing an expanded pipeline of products from the melanocortin family, a class of drugs that includes afamelanotide. Two novel molecules have been announced: CUV9900 and VLRX001.
CUV9900 is an alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue. Initial research has shown that CUV9900 is a potent skin protectant. CLINUVEL intends to launch CUV9900 in various new formulations. Formulation work has commenced and CLINUVEL expects the first formulations to be available for clinical testing after the commercialisation of SCENESSE® in Europe.
VLRX001 is an addition to the family of melanocortin analogues which provoke increased and prolonged cellular activity. It contains a specific peptide sequence, designed to make it less susceptible to degradation than physiologic (natural) alpha-melanocyte stimulating hormone (α-MSH).
The VLRX001 development work was undertaken through CLINUVEL’s majority owned Singaporean subsidiary, VALLAURIX and has leveraged the knowledge gained from long term experience with the clinical use of SCENESSE®.
Formulation work will focus on the development of VLRX001 for topical self-administration by patients. The transdermal product will initially be evaluated as adjuvant maintenance therapy in the depigmentation disorder vitiligo.
Overall, the development of VLRX001 is part of CLINUVEL’s life cycle management of its portfolio of products to ensure long term use and value of its technology and assets. CLINUVEL will hold all rights to the final product and indications through VALLAURIX.
CLINUVEL’s development pipeline
Last updated May 22, 2015